With tightening budgets and increasing pressure to de-risk R AND D, pharma and biotech are shifting their focus toward smarter, more efficient drug design. Companies are investing more in enabling technologies-from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM, NMR, and X-ray crystallography-to improve rational drug design and enhance decision-making early in discovery.

While AI-powered structure prediction is transforming the landscape-recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2- its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery.

Time: 9:00 AM – 5:00 PM

Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States

Prices: USD 2599.00 – USD 5197.00

Speakers: Alexey Rak Scientific Fellow, Head of BioStructure and Biophysics Sanofi, Ann Boriack-Sjodin Executive Director and Global Head of Structural Biology Takeda Pharmaceuticals, Benoit Moreau Head of Medicinal Chemistry Remix Therapeutics, Dave Brown Senior Director, Structural Biology and Biophysics Vertex Pharmaceuticals, and more